menin

CHARM Therapeutics raises $80 million in Series B financing to advance development of best-in-class menin inhibitor for AML

New investors NEA and SR One lead round alongside existing investors OrbiMed, F-Prime, NVIDIA and Khosla VenturesCHARM’s AI-designed menin inhibitor…

3 months ago